BioSpace News Archive

Remix Therapeutics today announced that the Company will be participating in the 6th Annual RNA-Targeted Drug Discovery & Development Summit taking place December 12-14, 2023.

Agenus Inc. today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody.

Erasca, Inc. (Nasdaq: ERAS) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm).

Pasithea Therapeutics Corp. today announced positive preclinical results from two in vivo studies evaluating the anti-tumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.

NeuroOne Medical Technologies Corporation today announced that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance to market its OneRF™ Ablation System for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures.

Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ET.

Terumo Medical Corporation is pleased to announce the launch of its new AZUR HydroPack Peripheral Coil System in the United States.

Shanghai Yingli Pharmaceutical Co., Ltd. today announced the pivotal Phase 2 clinical trial results of the investigation of linperlisib in the treatment of patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL).

Zhongchao Inc. announced that Shanghai Zhongxin Medical Technology Co., Ltd., of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has renewed its service agreement with Beijing Public Health Foundation, a non-profit organization dedicated to enhancing Chinese citizens’ health through public welfare initiatives and aid programs.

Curis, Inc. last night presented clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference.